Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
CARL · against 410 other Healthcare companies of similar size
Ranked #259 of 411 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score153 peers with a valuation score of 0–9, including CARL · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | CARL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 397 reported | -8.1% | 0.0% | 31% | 30% | |
| EBITDA yieldHigher is better · 416 reported | -11.7% | 3.0% | 20% | 50% | |
| Free cash flow yieldHigher is better · 195 reported | -9.1% | -8.4% | 48% | 20% | |
| Book yieldHigher is better · 408 reported | 21.5% | 50.4% | 19% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 259 | 293M USD | 8 | ||
| 259 | 241M USD | 8 | ||
| 259 | 675M USD | 8 | ||
| 259 | 479M USD | 8 | 34 | |
| 259 | 393M USD | 8 | 50 | |
| 259 | 395M USD | 8 | 30 | |
| 259 | 296M USD | 8 | 26 | |
| 259 | 560M USD | 8 | 42 | |
| 259 | 775M USD | 8 | 31 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score